Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 2/20 | 0.58 |
| ▸ | GPR139 | Q6DWJ6 | 2/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3069332 | 1.00 | MAPT (0.71) | MAPTALDH1A1PKMHPGDGPR139 | |
| SCHEMBL692819 | 1.00 | MAPT (0.71) | MAPTALDH1A1PKMHPGDGPR139 | |
| SCHEMBL27892108 | 0.90 | MAPT (0.67) | MAPTALDH1A1PKMHPGDGPR139 | |
| SCHEMBL9516620 | 0.86 | MAPT (0.82) | MAPTALDH1A1PKMHPGDGPR139 | |
| SCHEMBL3677980 | 0.86 | MAPT (0.67) | MAPTALDH1A1PKMHPGDGPR139 | |
| SCHEMBL23080142 | 0.86 | MAPT (0.71) | MAPTALDH1A1PKMHPGDGPR139 | |
| SCHEMBL16975095 | 0.86 | MAPT (0.71) | MAPTALDH1A1PKMHPGDGPR139 | |
| SCHEMBL18241727 | 0.86 | MAPT (0.71) | MAPTALDH1A1PKMHPGDGPR139 | |
| SCHEMBL6400133 | 0.84 | MAPT (0.69) | MAPTALDH1A1PKMHPGDGPR139 | |
| SCHEMBL31373866 | 0.84 | MAPT (0.69) | MAPTALDH1A1PKMHPGDGPR139 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250135005-A1 | PROCESSES FOR PREPARING FUNCTIONALIZED CYCLOOCTENES | TAMBO INC (US) | 2025-05-01 | — | — | US | disclosed |
| US-12194100-B2 | Processes for preparing functionalized cyclooctenes | TAMBO, INC. (US) | 2025-01-14 | — | — | US | disclosed |
| US-20210346502-A1 | PROCESSES FOR PREPARING FUNCTIONALIZED CYCLOOCTENES | TAMBO INC (US) | 2021-11-11 | — | — | US | disclosed |
| WO-2014009964-A1 | PROCESS FOR ENANTIOMERIC ENRICHMENT OF 2 ', 6 ' - PIPECOLOXYLIDIDE | NEON LABORATORIES LIMITED (IN) | 2014-01-16 | — | — | WO | disclosed |
| US-20100222257-A1 | SUBSTITUTED PHENETHYLAMINES | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-09-02 | — | — | US | disclosed |
| US-7745665-B2 | Substituted phenethylamines | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-06-29 | — | — | US | disclosed |
| US-20090203763-A1 | SUBSTITUTED BENZHYDRYLETHERS | AUSPEX PHARMACEUTICALS, INC. (US) | 2009-08-13 | — | — | US | disclosed |
| WO-2009094457-A2 | SUBSTITUTED BENZHYDRYLETHERS | AUSPEX PHARMACEUTICALS (US) | 2009-07-30 | — | — | WO | disclosed |
| WO-2009077173-A2 | DNA-ENCODED CHEMICAL LIBRARIES | PHILOCHEM AG (CH) | 2009-06-25 | — | — | WO | disclosed |
| US-20080300316-A1 | isotopically enriched phenylephrine derivatives, used for the treatment and/or management of nasal congestion, headaches, asthma, chronic obstructive pulmonary diseases, ischemia, hypotension, and/or any disorder ameliorated by modulating alpha-adrenergic receptors | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-12-04 | — | — | US | disclosed |
| US-20060264493-A1 | Tetracyclic pyrazole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PFIZER ITALIA S.R.L. (IT) | 2006-11-23 | — | — | US | disclosed |
| EP-1185869-B1 | LIGAND-ANCHOR CONJUGATES FOR PRODUCING A BIOSENSOR LAYER | GRAFFINITY PHARMACEUTICALS AG (DE) | 2006-07-26 | — | — | EP | disclosed |
| US-20050153357-A1 | Bioactive sensors | EICHLER JUTTA (DE) | 2005-07-14 | — | — | US | disclosed |
| US-20050059657-A1 | Aminoisoxazole derivatives active as kinase inhibitors | PFIZER ITALIA S.R.L. (IT) | 2005-03-17 | — | — | US | disclosed |
| US-20020127577-A1 | Bioactive sensors | GRAFFINITY PHARMACEUTICALS AG (DE) | 2002-09-12 | — | — | US | disclosed |
| EP-1185869-A2 | LIGAND-ANCHOR CONJUGATES FOR PRODUCING A BIOSENSOR LAYER | Graffinity Pharmaceutical Design GmbH (DE) | 2002-03-13 | — | — | EP | disclosed |
| EP-1091958-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2001-04-18 | — | — | EP | disclosed |
| WO-2000073796-A2 | LIGAND-ANCHOR CONJUGATES FOR PRODUCING A BIOSENSOR LAYER | GRAFFINITY PHARMACEUTICAL DESIGN GMBH (DE) | 2000-12-07 | — | — | WO | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059657-A1 | Aminoisoxazole derivatives active as kinase inhibitors | MAP3K9, MAP3K19, MAP4K2 | MAPT 281/4885ALDH1A1 4444/4885PKM 377/4885 |
| US-20060264493-A1 | Tetracyclic pyrazole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | MAP3K1, MAP3K19, MAP3K20 | MAPT 639/4885ALDH1A1 4446/4885PKM 503/4885 |
| US-20080300316-A1 | isotopically enriched phenylephrine derivatives, used for the treatment and/or management of nasal congestion, headaches, asthma, chronic obstructive pulmonary diseases, ischemia, hypotension, and/or any disorder ameliorated by modulating alpha-adrenergic receptors | ADRB1, ADRB2, ADRA1A | MAPT 2007/4885ALDH1A1 1022/4885PKM 531/4885 |
| US-12194100-B2 | Processes for preparing functionalized cyclooctenes | PPOX, SCO2, CYCS | MAPT 4086/4885ALDH1A1 4078/4885PKM 1564/4885 |
| US-20090203763-A1 | SUBSTITUTED BENZHYDRYLETHERS | UGT2B7, CYP3A7, CYP3A43 | MAPT 2684/4885ALDH1A1 103/4885PKM 773/4885 |
| US-20210346502-A1 | PROCESSES FOR PREPARING FUNCTIONALIZED CYCLOOCTENES | PPOX, SCO2, CYCS | MAPT 4086/4885ALDH1A1 4078/4885PKM 1564/4885 |
| US-20250135005-A1 | PROCESSES FOR PREPARING FUNCTIONALIZED CYCLOOCTENES | PPOX, SCO2, CYCS | MAPT 4086/4885ALDH1A1 4078/4885PKM 1564/4885 |
| US-20100222257-A1 | SUBSTITUTED PHENETHYLAMINES | ADRB1, ADRA2C, ADRB2 | MAPT 1647/4885ALDH1A1 489/4885PKM 366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.